Additionally, for ebselen to become a clinically acceptable radioprotector, there is also a need for establishing its selective radioprotective effects without compromising the tumor radiosensitivity
GLP-1R Race in 2025: 8 Essential Takeaways Drug Developers Need to Know Currently Playing Post:GLP-1R Race in 2025: 8 Essential Takeaways Drug Developers Need to Know In late 2025, a seemingly narrow advertising dispute told a much bigger story about the GLP-1 market
Xie F, Hu Q, Cai Q, Yao R, Ouyang S
Its about building habits that protect your research from the ground up
Diabetologia 47:10711078 Lu S, Yin H, Oriana H, Azoulay L (2022) Incretin-based drugs and the incidence of prostate cancer among patients with type 2 diabetes
If you have tried many interventions already, sharing this information with your healthcare provider can make it possible to advocate on your behalf to an insurance provider to prove that other attempts have been unsuccessful